Abstract
Objective This study evaluated the relationship between serum levels of endogenous secretory receptor for advanced glycation endproducts (esRAGE) and coronary plaque progression in diabetic and nondiabetic patients. Design and methods Serum esRAGE level was measured and quantitative coronary angiography (QCA) was performed in 265 consecutive patients at baseline and 1-year follow-up. Results Comparing to baseline, serum esRAGE level was significantly increased during follow-up in nondiabetic patients without plaque progression ( p = 0.014), unchanged in nondiabetic patients with plaque progression and diabetic patients without plaque progression, and decreased in diabetic patients with plaque progression ( p = 0.011). Moreover, change of esRAGE levels correlated with change of QCA measurements. Multivariable regression analyses revealed that high-density lipoprotein cholesterol (OR = 0.214, p = 0.037), hypertension (OR = 2.755, p = 0.011), high-sensitivity C-reactive protein (OR = 1.083, p < 0.001) and change of esRAGE (OR = 23.477, p < 0.001) were independent risk factors for plaque progression in diabetic patients. Conclusions This study demonstrated an association of decreased serum esRAGE level with coronary plaque progression in patients with diabetes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
